Synairgen (LON:SNG) announced its earnings results on Tuesday. The company reported GBX (3.11) (($0.04)) earnings per share (EPS) for the quarter, Digital Look Earnings reports.
LON:SNG traded down GBX 9.50 ($0.12) during trading hours on Thursday, hitting GBX 146 ($1.91). 1,551,277 shares of the stock traded hands, compared to its average volume of 3,251,946. Synairgen has a fifty-two week low of GBX 5.50 ($0.07) and a fifty-two week high of GBX 260 ($3.40). The firm has a market cap of $218.17 million and a price-to-earnings ratio of -40.56. The firm has a 50 day moving average price of GBX 201.24 and a 200 day moving average price of GBX 102.35. The company has a current ratio of 2.07, a quick ratio of 1.99 and a debt-to-equity ratio of 14.56.
Separately, FinnCap reissued a “corporate” rating on shares of Synairgen in a research note on Monday, July 20th.
Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-ß that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Featured Story: Learning About the VIX – Volatility Index
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.